ClinicalTrials.gg
RecruitingNCT06150677Updated Jan 5, 2024

Effects of Static Apnea at High Lung Volume on Hypoalgesia, Cardiovascular Function and Respiratory Function

A Phase 3 interventional study of Voluntary apnoea in Pain, Hypoxia and Hypercapnia, sponsored by Centro Universitario La Salle. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Centro Universitario La Salle · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.
Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of this randomized controlled study is to explore the hypoalgesic response of a 6 minutes of intermittent static apneas training session at high lung volume in healthy subjects; also, as secondary objectives, to analyze the cardiovascular and respiratory response produced during the intervention.

02

Conditions studied

  • Pain
  • Hypoxia
  • Hypercapnia
  • Apnea
03

In context

Pain

10,054 studies on the registry are indexed under Pain; 1,649 are open to participants now.

This study's planned enrollment of 60 is close to the median of 66 across 8,493 interventional studies indexed under Pain.

Browse Pain studies →

Lead sponsor

Centro Universitario La Salle is the lead sponsor of 25 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asymptomatic subjects aged between 18 and 64 years.

Exclusion criteria

Exclusion Criteria:

  • Cardiovascular, respiratory, metabolic, neurological or osteomuscular signs or pathologies.
  • History of epilepsy.
  • Pregnant.
  • Pharmacological treatment.
  • Participants who present any type of pain on the day of the measurements or who have frequently suffered pain during the previous 4 weeks.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Static apnea at High Lung Volume

    Participants will remain at rest in the supine position for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 30 seconds, followed by a normal breath of 10 seconds (9 cycles of 30s apnea - 10s normal breathing, until completing the 6 minutes).

    Other: Voluntary apnoea

  • No intervention
    Static at normal breathing

    Participants will remain at rest in the supine position for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes

Interventions

  • OtherVoluntary apnoea

    Static apneas at high lung volume with a density of 30 seconds, followed by a normal breath of 10 seconds (9 cycles of 30s apnea - 10s normal breathing, until completing the 6 minutes).

06

What researchers measure

Primary outcomes

  1. Pain pressure threshold (PPT) on thumb, anterior tibial and spinous process of C7

    PPT is tested on the dorsal base of the distal phalanx of the thumb on the dominant side and on the muscle belly of the tibialis anterior on the dominant side. The region to be pressed is marked with a pen. The patient is instructed to report with the first appearance of the sensation of "discomfort". An ascending ramp of 0.5 kg/cm/s is applied, at the rhythm of a metronome. The measurement is started on the thumb, and alternated with tibia and C7 until 3 measurements of each region are obtained, enough time to give 30 seconds of rest between measurements in the same region. This protocol has demonstrated high inter-observer reliability measuring healthy subjects (ICC = 0.91).

    Time frame: before and after intervention (up 30 minutes)

Secondary outcomes

  1. Perceived Stress Scale (PSS)

    14-item questionnaire about their thoughts and feelings in the last month. The scale has a range of scores from 0 to 56. The lower the score, the more favorable for the patient's health.

    Time frame: before intervention (up 5 minutes)

  2. Pittsburg Sleep Quality Index (PSQI)

    9-item questionnaire on sleep quality in the past month. The scale has a range of scores from 0 to 21. The lower the score, the more favorable for the patient's health.

    Time frame: before intervention (up 5 minutes)

  3. Global Physical Activity Questionnaire (GPAQ)

    6-item questionnaire on the level of physical activity at work, for commuting and in leisure time. A higher score means higher weekly physical activity

    Time frame: before intervention (up 5 minutes)

  4. Oxygen saturation

    Oxygen saturation will be measured during the procedure by finger pulse oximetry.

    Time frame: during intervention (up 6 minutes)

  5. Heart rate

    Heart rate will be measured during the procedure by finger pulse oximetry.

    Time frame: during intervention (up 6 minutes)

  6. Blood pressure

    Systolic and diastolic blood pressure will be measured before, during and immediately after the procedure using a digital wrist sphygmomanometer.

    Time frame: before, during and after intervention (up 10 minutes)

  7. Rate of perceived exertion (RPE)

    RPE Borg CR-10 is used to measure how hard your body works during physical activity. It runs from 0 - 10, using numbers to rate how much effort an activity takes.

    Time frame: immediately after intervention (up 10 seconds)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for May 2025, 17 months after the start.

Of 110 non-industry phase 3 interventional studies under Pain, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 17 months is below that.

Counting every sponsor, half of 215 studies reached it within 18 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2023
First posted
Nov 29, 2023
StartActual
Dec 1, 2023
Primary completionEst.
May 1, 2025
CompletionEst.
May 1, 2025
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06150677
Lead sponsor
Centro Universitario La Salle
Responsible party
Fran de Asís Fernández (Director, Centro Universitario La Salle) — Principal investigator
First posted
Nov 29, 2023
Start date
Dec 1, 2023
Primary completion
May 1, 2025 (estimated)
Completion
May 1, 2025 (estimated)
Last update
Jan 5, 2024

Study contacts

Fran DeAsís-Fernández
Contact
frandeasis@lasallecampus.es
(0034)667000218

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion